Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy

Novo Nordisk NOVO.B 7.55%increase; green up pointing triangle shares climbed after U.S. regulators approved a tablet version of Ozempic and Wegovy, paving the way for the Danish drugmaker to start selling the first GLP-1 weight-loss pill.

The Food and Drug Administration’s green light is expected to broaden the use of the class of drugs to which Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s LLY 0.47%increase; green up pointing triangle Zepbound and Mounjaro belong, ushering in a new era of the obesity-drug revolution.